Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
The first Phase 3 trial to report results, TRIUMPH-4, was published on 11 December 2025
Some people with known GI sensitivity also benefit from starting their first injection in the evening
Retatrutide pushes more patients to 25%+
(Gross spending does not account for any rebates paid by drug manufacturers to pharmacy benefit managers, which would result in lower net Medicare spending.) Gross spending on Ozempic alone increased from $2.6 billion in 2021 to $4.6 billion in 2022, pushing it to 6th place among the top-selling drugs in Medicare Part D that year, up from 10th place the year before
US$ 27.27
US$ 27.47
US$ 28.39
US$ 20.90
US$ 21.88
US$ 22.22
US$ 28.10
US$ 26.26
US$ 28.56
